Site icon OncologyTube

ROS1+ NSCLC: Chemotherapy and Immunotherapy –

Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Alejandro Calvo examines the use of chemotherapy and immunotherapy in ROS1+ NSCLC.

We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech

For more, please visit http://cancerGRACE.org/.
To join the conversation, visit https://cancergrace.org/forum.

Exit mobile version